Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wouter Jukema

Showing results (701-710 of 928) with videos related to

Pageof 93
Sort By:
Circulation|February 7, 2007
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Naveed Sattar, Heather M Murray, Alex McConnachie, et al.
Expert Opinion on Therapeutic Targets|January 26, 2010
Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary interventionPascalle S Monraats, Yue Fang, Douwe Pons, et al.
ESC Heart Failure|June 22, 2021
Identification of sex-specific biomarkers predicting new-onset heart failureAnne Raafs, Job Verdonschot, João Pedro Ferreira, et al.
American Heart Journal|December 19, 2006
MISSION!: optimization of acute and chronic care for patients with acute myocardial infarctionSu-San Liem, Barend L van der Hoeven, Pranobe V Oemrawsingh, et al.
European Heart Journal|October 14, 2020
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trialMichael Szarek, Vera A Bittner, Philip Aylward, et al.
Pharmacogenetics and Genomics|September 27, 2006
Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary interventionPascalle S Monraats, Florentine de Vries, Laura W de Jong, et al.
Lancet (London, England)|November 30, 2002
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialJames Shepherd, Gerard J Blauw, Michael B Murphy, et al.
Journal of the American College of Cardiology|May 9, 2020
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES TrialDeepak L Bhatt, Andrew H Briggs, Shelby D Reed, et al.
European Heart Journal. Imaging Methods and Practice|February 26, 2026
Adults with anomalous aortic origin of a coronary artery: impact of invasive functional testing on clinical decision making-insights from the MuSCAT registryDiederick B H Verheijen, Anastasia D Egorova, Frank van der Kley, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 18, 2016
Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerationsJ Wouter Jukema, Maddalena Lettino, Petr Widimský, et al.
Pageof 93

Showing results (701-710 of 928) with videos related to

Sort By:
Pageof 93
Circulation|February 7, 2007
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Naveed Sattar, Heather M Murray, Alex McConnachie, et al.
Expert Opinion on Therapeutic Targets|January 26, 2010
Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary interventionPascalle S Monraats, Yue Fang, Douwe Pons, et al.
ESC Heart Failure|June 22, 2021
Identification of sex-specific biomarkers predicting new-onset heart failureAnne Raafs, Job Verdonschot, João Pedro Ferreira, et al.
American Heart Journal|December 19, 2006
MISSION!: optimization of acute and chronic care for patients with acute myocardial infarctionSu-San Liem, Barend L van der Hoeven, Pranobe V Oemrawsingh, et al.
European Heart Journal|October 14, 2020
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trialMichael Szarek, Vera A Bittner, Philip Aylward, et al.
Pharmacogenetics and Genomics|September 27, 2006
Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary interventionPascalle S Monraats, Florentine de Vries, Laura W de Jong, et al.
Lancet (London, England)|November 30, 2002
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialJames Shepherd, Gerard J Blauw, Michael B Murphy, et al.
Journal of the American College of Cardiology|May 9, 2020
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES TrialDeepak L Bhatt, Andrew H Briggs, Shelby D Reed, et al.
European Heart Journal. Imaging Methods and Practice|February 26, 2026
Adults with anomalous aortic origin of a coronary artery: impact of invasive functional testing on clinical decision making-insights from the MuSCAT registryDiederick B H Verheijen, Anastasia D Egorova, Frank van der Kley, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 18, 2016
Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerationsJ Wouter Jukema, Maddalena Lettino, Petr Widimský, et al.
Pageof 93